Literature DB >> 15726352

Is whole-body FDG-PET valuable for health screening? For.

Michiru Ide1, Yutaka Suzuki.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 15726352     DOI： 10.1007/s00259-005-1774-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  17 in total

Review 1.  Ten criteria for effective screening: their application to multislice CT screening for pulmonary and colorectal cancers.

Authors:  N A Obuchowski; R J Graham; M E Baker; K A Powell
Journal:  AJR Am J Roentgenol       Date:  2001-06       Impact factor: 3.959

2.  Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumors.

Authors:  Y Iwata; S Shiomi; N Sasaki; H Jomura; S Nishiguchi; S Seki; J Kawabe; H Ochi
Journal:  Ann Nucl Med       Date:  2000-04       Impact factor: 2.668

Review 3.  From PET detectors to PET scanners.

Authors:  John L Humm; Anatoly Rosenfeld; Alberto Del Guerra
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-10-02       Impact factor: 9.236

4.  Optimization of urinary FDG excretion during PET imaging.

Authors:  J K Moran; H B Lee; M D Blaufox
Journal:  J Nucl Med       Date:  1999-08       Impact factor: 10.057

5.  Cancer screening with whole-body 18F-fluorodeoxyglucose positron-emission tomography.

Authors:  S Yasuda; A Shohtsu
Journal:  Lancet       Date:  1997 Dec 20-27       Impact factor: 79.321

Review 6.  Whole-body FDG-PET imaging in the management of patients with cancer.

Authors:  Roland Hustinx; François Bénard; Abass Alavi
Journal:  Semin Nucl Med       Date:  2002-01       Impact factor: 4.446

7.  Dual time point 18F-FDG PET for the evaluation of pulmonary nodules.

Authors:  Alexander Matthies; Marc Hickeson; Andrew Cuchiara; Abass Alavi
Journal:  J Nucl Med       Date:  2002-07       Impact factor: 10.057

Review 8.  Value of whole-body FDG PET in management of lung cancer.

Authors:  Kotaro Higashi; Ichiro Matsunari; Yoshimichi Ueda; Ryosuke Ikeda; Jianfei Guo; Manabu Oguchi; Hisao Tonami; Itaru Yamamoto
Journal:  Ann Nucl Med       Date:  2003-02       Impact factor: 2.668

Review 9.  Clinical applications of PET in oncology.

Authors:  Eric M Rohren; Timothy G Turkington; R Edward Coleman
Journal:  Radiology       Date:  2004-03-24       Impact factor: 11.105

Review 10.  Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging.

Authors:  Gary J R Cook; Eva A Wegner; Ignac Fogelman
Journal:  Semin Nucl Med       Date:  2004-04       Impact factor: 4.446
View more
  10 in total

1.  The efficiency of healthcare facilities providing PET cancer screening in Japan.

Authors:  Xuanxiu Liu
Journal:  Jpn J Radiol       Date:  2011-12-23       Impact factor: 2.374

2.  Hybrid method for the detection of pulmonary nodules using positron emission tomography/computed tomography: a preliminary study.

Authors:  Atsushi Teramoto; Hiroshi Fujita; Katsuaki Takahashi; Osamu Yamamuro; Tsuneo Tamaki; Masami Nishio; Toshiki Kobayashi
Journal:  Int J Comput Assist Radiol Surg       Date:  2013-06-23       Impact factor: 2.924

3.  Low Cancer Incidence in Naked Mole-Rats May Be Related to Their Inability to Express the Warburg Effect.

Authors:  Pedro Freire Jorge; Matthew L Goodwin; Maurits H Renes; Maarten W Nijsten; Matthew Pamenter
Journal:  Front Physiol       Date:  2022-05-04       Impact factor: 4.755

4.  The value of F-18 fluorodeoxyglucose positron emission tomography/computed tomography in asymptomatic examinees with unexplained elevated blood carcinoembryonic antigen levels.

Authors:  Wenfeng Li; Weiwei Yin; Rongying Ou; Ting Chen; Lingling Xiong; Dezhi Cheng; Deyao Xie; Xiangwu Zheng; Yunsheng Xu; Liang Zhao
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-24       Impact factor: 9.236

5.  Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells.

Authors:  Jared J Barrott; Philip F Hughes; Takuya Osada; Xiao-Yi Yang; Zachary C Hartman; David R Loiselle; Neil L Spector; Len Neckers; Narasimhan Rajaram; Fangyao Hu; Nimmi Ramanujam; Ganesan Vaidyanathan; Michael R Zalutsky; H Kim Lyerly; Timothy A Haystead
Journal:  Chem Biol       Date:  2013-09-12

6.  Comparison of FDG-PET/CT for Cancer Detection in Populations With Different Risks of Underlying Malignancy.

Authors:  Hung-Pin Chan; Wen-Shan Liu; Wen-Shiung Liou; Chin Hu; Yu-Li Chiu; Nan-Jing Peng
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

7.  Quantitative Analysis of Torso FDG-PET Scans by Using Anatomical Standardization of Normal Cases from Thorough Physical Examinations.

Authors:  Takeshi Hara; Tatsunori Kobayashi; Satoshi Ito; Xiangrong Zhou; Tetsuro Katafuchi; Hiroshi Fujita
Journal:  PLoS One       Date:  2015-05-28       Impact factor: 3.240

8.  What Is the Clinical Significance of FDG Unexpected Uptake in the Prostate in Patients Undergoing PET/CT for Other Malignancies?

Authors:  Priya Bhosale; Aparna Balachandran; Raghu Vikram; Chitra Viswanathan; Homer Macapinlac; Eric Rohren; Ramanujan Prativadi
Journal:  Int J Mol Imaging       Date:  2013-12-28

9.  Application of whole-body FDG-PET for cancer screening in a cohort of hospital employees.

Authors:  Chin Hu; Chun-Peng Liu; Jin-Shiung Cheng; Yu-Li Chiu; Hung-Pin Chan; Nan-Jing Peng
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

10.  The current status of an FDG-PET cancer screening program in Japan, based on a 4-year (2006-2009) nationwide survey.

Authors:  Ryogo Minamimoto; Michio Senda; Seishi Jinnouchi; Takashi Terauchi; Tsuyoshi Yoshida; Takeshi Murano; Hiroshi Fukuda; Takeshi Iinuma; Kimiichi Uno; Sadahiko Nishizawa; Eriko Tsukamoto; Hiroshi Iwata; Takeshi Inoue; Kazuhiro Oguchi; Rumi Nakashima; Tomio Inoue
Journal:  Ann Nucl Med       Date:  2012-10-20       Impact factor: 2.668
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.